Professional Background Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia.
Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and …
More about me
- Last name
- Fuad El-Hibri
- Date of birth
- 19/04/1953
- Location
- (Baden-Wurttemberg)
Germany
- Native language
- English
- Company
- BioSolutions Inc.
- Profession
- Business & Administration (Manager)
- Tags
-
Notwithstanding anything to the contrary in Exhibit I to the August 9, 2006 Letter from
Emergent BioSolutions Inc. (the “Company”) to
Fuad El-Hibri, Mr. El-Hibri and the Company hereby acknowledge and agree as follows:
|
1. |
|
The Company acknowledges that Mr. El-Hibri is a member of the board of trustees of American University, a member of the board of directors of the International BioMedical Research Alliance, and director and treasurer of the El-Hibri Charitable Foundation; that Mr. El-Hibri also serves as a director and/or officer of Digicel Holdings, Ltd., Telectronics, Inc., East West Resources Corporation, Intervac LLC, and Intervac Management LLC; and that Mr. El-Hibri manages certain of his own personal investments, including real estate holding companies. The Company agrees that Mr. El-Hibri’s service in such capacities has not interfered with his ability to perform his duties to the Company and, assuming continued service in such capacities at levels of time and attention comparable to those that Mr. El-Hibri has provided to such entities within the preceding twelve months, would not violate Exhibit I or interfere with Mr. El-Hibri’s ability to perform his duties to the Company. |
|
|
2. |
|
It shall not be a violation of Exhibit I for Mr. El-Hibri to pursue any business transaction or opportunity where such transaction or opportunity was first presented (i) to Mr. El-Hibri in his capacity as an officer or director of the entities identified in Paragraph 1, above or (ii) to the Company, and the Board of Directors of the Company declined to pursue such transaction or opportunity. |
|
|
3. |
|
With respect to Mauro Gibellini, Jose Ochoa, and Kerry Kisling, three employees who, at Mr. El-Hibri’s invitation, left their employment with East West Resources Corporation (EWR) to accept employment with the Company, it shall not be a violation of Exhibit I for Mr. El-Hibri to induce, counsel, advise, solicit or encourage, or attempt to induce, counsel, advise, solicit or encourage those employees to return to employment with EWR. |
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=4774f870-bbc8-48b0-b1b7-8a2468923196)
Mr. Fuad El-Hibri has served as chief executive officer and as chairman of the board of directors of Emergent BioSolutions since June 2004 and as president since March 2006. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of a corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. The Company subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=165db3a3-1c90-4c5d-a2c1-b95148c64df4)
Tags: Board of directors, Chief Executive Officer, Company, Corporation, Stanford University, Subsidiary, University of Oxford, Venture capital, Yale University
Chairman of the Board, Chief Executive Officer, Emergent BioSolutions, Fuad El-Hibri | admin | 
Comments (0)
Mr. Fuad El-Hibri has served as chief executive officer and chairman of the board of directors since June 2004 and as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of our corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. We subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=e323c2cf-8f30-46d8-a116-c9ef3ec11230)
Tags: Board of directors, Chief Executive Officer, Corporation, Stanford University, Subsidiary, University of Oxford, Venture capital, Yale University
BioPort Corporation, Chairman of the Board, Chairman of the Board of Directors, Chief Executive Officer, Emergent, Emergent BioSolutions, Fuad El-Hibri | admin |
Comments (0)
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=f334a4f1-233a-4012-9ccc-11caee122aaa)
